9轮融资、众多头部机构加持,减肥药明星企业今日IPO

动脉网
May 27, 2025

今日,慢性病创新疗法研发公司派格生物在港交所上市。派格生物重点聚焦代谢紊乱领域,公司核心产品——GLP-1受体激动剂PB-119(维培那肽注射液)预计2025年上市,主要用于T2DM及肥胖症的一线治疗。同时,派格生物还在T2DM、超重或肥胖症、NASH、先天性高胰岛素血症等治疗领域布局了另外五款候选药物。在火热的T2DM及减肥赛道,派格生物是一级市场的明星项目。招股书显示,在IPO之前,派格生物于...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10